Case report

*Mycobacterium mucogenicum* bacteremia in an immunocompetent host: A case report and concise review

N. Beydoun\(^a,^*\), Z. Wiley\(^b\), N. Rouphael\(^b,c\)

\(^a\) Emory University School of Medicine, Department of Internal Medicine, Atlanta, GA, USA
\(^b\) Emory University School of Medicine, Department of Internal Medicine, Division of Infectious Diseases, Atlanta, GA, USA
\(^c\) The Hope Clinic of the Emory Vaccine Center, Emory University, Decatur, GA, USA

**A R T I C L E  I N F O**

Article history:
Received 22 May 2020
Received in revised form 15 December 2020
Accepted 17 December 2020

Keywords:
Rapidly growing mycobacterium
*Mycobacterium mucogenicum*
Peripherally inserted central catheter
Bloodstream infection

**A B S T R A C T**

Rapidly growing mycobacterium (RGM) bloodstream infections (BSI) have been described in the literature mostly in immunocompromised patients such as those with malignancies. Here, we describe a case of a RGM, *Mycobacterium mucogenicum*, bloodstream infection in an immunocompetent host who was receiving antibiotics via a peripherally inserted central catheter (PICC).

© 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license ([http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/)).

**Introduction**

Around 800,000 cases of central venous catheter (CVC) related BSI are diagnosed in the United States each year in intensive care setting [1]. Depending on the type of catheter, method of insertion and duration of catheter placement, the risk of BSI varies [2]. The most commonly isolated microorganisms that cause Catheter-Related Bloodstream Infections (CRBSI) are: coagulase-negative Staphylococcus, Staphylococcus aureus, *Candida* species, and enteric gram-negative rods [2]. Rarely, acid-fast bacilli (AFB) can be a cause of BSI, mostly in immunocompromised patients with CVCS. Therefore, it is important to recognize these infections promptly in order to administer the appropriate antibiotic regimen.

**Case presentation**

A 54-year-old Caucasian woman presented with fever and body aches. Two months earlier, she had undergone anterior cervical disectomy and fusion of C6-C7 for cervical spondylosis and myelopathy, after which she had wound dehiscence and infection with Methicillin Resistant *Staphylococcus aureus* (MRSA) proven by culture. She was undergoing treatment with daptomycin intravenously, after intolerance of her initial regimen of vancomycin and rifampin.

Her medical history included breast cancer (bilateral mastectomy and chemotherapy 8 years prior) and prior cholecystectomy and appendectomy. Family and social histories were unremarkable.

On physical examination, vital signs were stable except for a temperature of 38.9°C. Her surgical wound site was completely healed. The peripherally inserted central catheter (PICC) site was mildly tender without warmth, swelling, or discharge.

Laboratory results included: white blood cells (WBCs) count of 13,100/mcl. (normal range 4,000–10,000/mcl.), erythrocyte sedimentation rate of 55 mm/h (reference high >30 mm/h), C-reactive protein (CRP) of 52 mg/L (reference high >10 mg/L). Her HIV test was negative. Nine out of nine blood cultures were positive for AFB. The catheter was removed and catheter tip culture grew more than 15 colonies of AFB. Upon further analysis and speciation, culture results were positive for *Mycobacterium mucogenicum* (Fig. 1).

The isolated *M. mucogenicum* was susceptible to amikacin, cefoxitin, ciprofloxacin, clarithromycin and trimethoprim/sulfamethoxazole. Intermediate resistance was noted for linezolid, and the isolate was resistant to doxycycline.

A four week course of meropenem, azithromycin and ciprofloxacin was initiated and repeat blood cultures drawn on the third day of therapy were negative. A week into therapy, a new PICC line was placed, before discharge. She also completed a ten week course of daptomycin for her MRSA wound infection. Repeat MRI and WBC scan showed no evidence of infection and her CRP decreased to 10 mg/L.
Discussion

With the increase of immunocompromising conditions, the prevalence of rapidly growing mycobacterium (RGM) infections has been rising [3]. This rise is also partly due to improved laboratory methodologies in the detection and rapid isolation of RGM species [4]. Some of the groups included under RGM are Mycobacterium fortuitum, Mycobacterium mucogenicum, Mycobacterium neoaurum, Mycobacterium abscessus, Mycobacterium cosmeticum, Mycobacterium Smegmatis, and Mycobacterium phlei. M. mucogenicum’s name is derived from the mucoid-like appearance of the isolates [5]. The mucoid surface helps these organisms with biofilm formation, making it an important culprit among catheter-related infections. M. mucogenicum is ubiquitous in the environment and can be present in both public and hospital water supplies. Multiple outbreaks in patients with CVCs have been traced back to water sources contaminated with M. mucogenicum. This happens mostly while flushing the catheter with tap water or contamination of the CVC while bathing [5,6].

In our review of the literature, we found 20 articles on M. mucogenicum BSI, with detailed clinical and microbiological information available on a total of 172 patients (Table 1).

Among the rapidly growing mycobacteria, M. mucogenicum was found to be the most common cause of BSI. The majority of M. mucogenicum BSI cases reported in the literature were seen in adult and pediatric patients with malignancies. Other underlying diseases included end stage renal disease, cirrhosis, sickle cell disease, thalassemia major, chronic gastrointestinal pathology and autoimmune diseases. The most important risk factor was the presence of CVCs, on which these organisms are capable of biofilm formation [4]. Management of these infections includes removal of the catheter and administration of appropriate antibiotics. Removal of the catheter has been shown to have favorable outcomes and leads to a decrease in the rate of relapse of M. mucogenicum bacteremia [7].

There are no treatment guidelines outlining the optimal choice of antibiotics or length of treatment necessary for the management of these infections; it is often based on expert opinion. RGM are inherently resistant to first-line antituberculous drugs such as isoniazid, rifampin, and pyrazinamide [4]. Fortunately, M. mucogenicum is considered to be one of the most susceptible strains amongst RGM, and susceptibility testing should be performed for the following antibiotics: amikacin, tobramycin, clarithromycin, doxycycline, minocycline, ciprofloxacin, imipenem, linezolid, and cefoxitin [25].

Several studies have shown good outcomes with the use of two or more antibiotics, for a period of around 4 weeks, owed to the highly susceptible nature of the strain to multiple antibiotics. A study by El Helou et al. found that regimens that included Amikacin were associated with lower relapse and better outcomes [7], suggesting its use as initial empiric treatment of RGM bacteremia. Rodriguez-Coste et al. recommend using clarithromycin, imipenem and amikacin as broad empiric therapy while waiting for sensitivity testing, since this combination will provide at least two active agents [3].

Upon review of the literature, the most frequently used combination of antibiotics was a macrolide plus a quinolone, commonly clarithromycin and ciprofloxacin, which generally lead to good outcomes.

The challenge of identifying M. mucogenicum as a cause of bacteremia is its slow growth as compared to other microorganisms responsible for catheter related BSI, such as Staphylococcus. RGM can take up to 7 days to grow on culture media, while blood cultures are usually incubated for only 5 days. The other challenge is that this organism is often thought of as affecting only the immunocompromised, however, it can also cause bacteremia in immunocompetent hosts, such as our patient. M. mucogenicum should be considered in any patient with a catheter in place and managed accordingly.

Author statement

Dr. Nour Beydoun contributed to the conception and design of the work, literature review, acquisition on data, analysis of data, drafting and revising the work. Dr. Nadine Roupheal contributed to the conception and design of the work, planning, interpretation of data, revising the work critically for important intellectual content. Dr. Zanthia Wiley contributed to the design of the work, analysis of data, and critically revising the work for important intellectual content.

All authors approved the final version published.
Table 1
Review of the literature on *Mycobacterium mucogenicum* bloodstream infections.

| Reference | Year | Total # of patients | # of patients with *M. mucogenicum* | Sex/Age (mean) | Underlying disease/comorbidity | Presence of CVC | Source | Treatment | Removal of CVC | Outcome |
|-----------|------|---------------------|-------------------------------------|----------------|--------------------------------|----------------|--------|------------|---------------|---------|
| [3]       | 2016 | 32                  | 9                                   | 44.4% M/55.9 (mean) | Malignancy (5) Chronic GI pathol (2) Autoimmune disease (1) | Yes (88.9%) | Not specified | Not specified | Not specified | Favorable (62.5 %) |
| [6]       | 2017 | 1                   | 1                                   | M/34            | ESRD on home HD                | Yes             | Tap water supply | MXF + CLR for 6 weeks | Yes         | Favorable |
| [7]       | 2013 | 116                 | 45                                  | 57.8% M/52 (median) | Malignancy                     | Yes (95.7 %) | Not specified | Most frequently: ML + FQ (60 %) | Yes (78.4 %) | Resolved (79.3 %) |
| [8]       | 2004 | 6                   | 6                                   | N/A (adults and pediatrics patients) 59% M/52 (median) | BMT or HSCT (5) Malignancy (1) | Yes (100 %) | Tap water supply | Not specified | Not specified | Not specified |
| [9]       | 2016 | 39                  | 39                                  | 50 % M/42.25 (mean) | Sickle-cell disease            | Yes (100 %) | Tap water supply | Combination >1 ABx | Yes (100 %) | Favorable |
| [10]      | 2011 | 5                   | 4                                   | 25 % M/26.75 (mean) | Malignancy                     | Yes (100 %) | Tap water supply | Combination >1 ABx | Yes (100 %) | Favorable |
| [11]      | 2008 | 5                   | 5                                   | 80 % M/9.1 (mean) | Malignancy                     | Yes (100 %) | Tap water supply | No ABx (50 %) AMK (25 %, for febrile neutropenia) IPM followed by CIP for 6 weeks (25 %) CLR (20 %) CLR + CIP (40 %) Amikacin (20 %) | Yes (100 %) | Favorable |
| [12]      | 2004 | 13                  | 2                                   | 50 % M/9 (mean) | Malignancy                     | Yes (100 %) | Tap water supply | AMK + CLR for 8 weeks (50 %) Multiple combinations for 24 weeks (50 %) | Yes (100 %) | Favorable |
| [13]      | 1998 | 1                   | 1                                   | M/47            | Cirrhosis                      | Yes             | Uncertain | IPM + AMK | Not specified | Defervesced but died of other causes |
| [14]      | 2007 | 115                 | 28                                  | 66% M/48.4 (mean) | Malignancy                     | Yes (100 %) | Not specified | Combination >1 ABx IV ABx for 2 – 4 weeks followed by PO ABx for 4 – 6 weeks (100%) | Yes (100 %) | Favorable (100 %) |
| [15]      | 2000 | 40                  | 2                                   | N/A             | HSCT                            | Yes (100 %) | Not specified | Combination >1 ABx | Yes (100 %) | Favorable (100 %) |
| [16]      | 2015 | 25                  | 2                                   | 100 % F/9 (mean) | Malignancy                     | Yes (100 %) | Not specified | Not specified | Not specified | Not specified |
| [17]      | 2010 | 39                  | 3                                   | N/A (adults and pediatrics patients) 50 % M/9 (mean) | Malignancy in majority | Not specified | Not specified | Not specified | Not specified | Not specified |
| [18]      | 2004 | 13                  | 2                                   | N/A             | Malignancy                     | Yes (100 %) | Not specified | No ABx (50 %) CLR + unspecific agent (50 %) IV AMK + PO CIP + PO CLR | Yes (100 %) | Favorable (100 %) |
| [19]      | 2006 | 1                   | 1                                   | F/6             | MDS s/p cord blood transplant   | Yes             | Tap water supply | Not specified | Not specified | Not specified |
| [20]      | 2008 | 5                   | 5                                   | 40 % M/67 (median) | Malignancy                     | Yes (100 %) | Tap water supply | Pima (kept Hickman) Then catheter removed and MRM + TEC + ACV due to relapse | Yes (100 %) | Favorable |

M=Male; N/A=Not applicable; GI=Gastrointestinal; ESRD=End stage renal disease; SCT=Stem cell transplant; BMT=Bone marrow transplant; HSCT=Hematopoietic stem cell transplant; MDS=Myelodysplasia syndrome; ALL=Acute lymphocytic leukemia; CVC=Central venous catheter; ABx=Antibiotics; PO=Orally; IV=Intravenous; MFX=Moxifloxacin; CLR=Clarithromycin; ML=Macrolide; FQ=Fluoroquinolone; AMK=Amikacin; IPM=Imipenem; CIP=Ciprofloxacin; MRM=Meropenem; TEC=Teicoplanin; ACV=Acyclovir.
All authors are in agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Funding

The present study had no sources of funding or sponsors. It was carried out with own resources of the authors.

Consent

Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.

Declaration of Competing Interest

The authors report no declarations of interest.

Acknowledgements

NB is supported by the Stimulating Access to Research in Residency of the National Institutes of Health under Award Number R38AI140299. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

References

[1] Mermel LA. Prevention of intravascular catheter-related infections. Ann Intern Med 2000;132(5):391–402, doi:http://dx.doi.org/10.7326/0003-4819-132-5-200003070-00005.
[2] Safdar N, Mermel LA, Lass DJ. The epidemiology of catheter-related infection in the critically ill. In: O’Grady N, Pittet D, editors. Catheter related infections in the critically ill. New York, NY: Klüver; 2004. p. 1–23.
[3] Rodriguez-Coste MA, Chica I, Steed LL, Salgado CD. Epidemiology of rapidly growing mycobacteria bloodstream infections. Am J Med Sci 2016;351(3):253–8, doi:http://dx.doi.org/10.1097/AMJ.0000000000001012.
[4] El Helou G, Viola GM, Hachem R, Han XY, Raad II. Rapidly growing mycobacterial bloodstream infections. Lancet Infect Dis 2013;13(2):166–74, doi:http://dx.doi.org/10.1016/S1473-3099(12)70316-X.
[5] Adekambi T. Mycobacterium tuberculosis group infections: a review. Clin Microbiol Infect 2009;15(10):911–8.
[6] Dhruve MJ, Bunce PE, D’Gama C, Chan CT. Case of Mycobacterium tuberculosis in home hemodialysis patient. Hemodial Int 2017;21(4):E79–81, doi:http://dx.doi.org/10.1111/hti.12574.
[7] El Helou G, Hachem R, Viola GM, El Zakhem A, Chaftari AM, Jiang Y, et al. Management of rapidly growing mycobacterial bacteremia in cancer patients. Clin Infect Dis 2013;56(6):843–6, doi:http://dx.doi.org/10.1093/cid/cis1032.
[8] Kline S, Cameron S, Streifel A, Yakrus MA, Kairis F, Peacock K, et al. An outbreak of bacteremias associated with Mycobacterium tuberculosis in a hospital water supply. Infect Control Hosp Epidemiol 2004;25(12):1042–9.
[9] Abidi MZ, Ledeboer N, Banerjee A, Hari P. Mycobacterium tuberculosis bacteremia in immune-compromised patients, 2008–2013. Diagn Microbiol Infect Dis 2016;85(2):182–5, doi:http://dx.doi.org/10.1016/j.diagmicrobio.2016.02.012.
[10] Tagashira Y, Kozai Y, Yamasa H, Sakurada M, Kashiyama T, Honda H. A cluster of central line-associated bloodstream infections due to rapidly growing nontuberculous mycobacteria in patients with hematologic disorders at a Japanese tertiary care center: an outbreak investigation and review of the literature. Infect Control Hosp Epidemiol 2015;36(1):76–80, doi:http://dx.doi.org/10.1017/ice.2014.14.
[11] Ashraf MS, Swinkler M, Augustino KL, Nobles D, Knupp C, Liles D, et al. Outbreak of Mycobacterium mucogenicum bloodstream infections among patients with sickle cell disease in an outpatient setting. Infect Control Hosp Epidemiol 2012;33(11):1132–6, doi:http://dx.doi.org/10.1086/668921.
[12] Baird SF, Taori SK, Dave J, Willocks LJ, Roddie H, Hanson M. Cluster of nontuberculous mycobacteremia associated with water supply in a haematology ward. J Hosp Infect 2011;79(4):339–43, doi:http://dx.doi.org/10.1016/j.jhin.2011.07.006.
[13] Shachor-Meyouhas Y, Sprecher H, Eluk O, Ben-Barak A, Kassis I. An outbreak of Mycobacterium mucogenicum bacteraemia in pediatric hematology-oncology patients. Pediatr Infect Dis J 2011;30(1):30–2, doi:http://dx.doi.org/10.1097/INF.0b013e3181ee3107.
[14] Livini C, Yaniv I, Samra Z, Kaufman I, Solter E, Ashkenazi S, et al. Outbreak of Mycobacterium mucogenicum bacteraemia due to contaminated water supply in a paediatric haematology-oncology department. J Hosp Infect 2008;70(3):253–8, doi:http://dx.doi.org/10.1016/j.jhin.2008.07.016.
[15] Hawkins C, Qi C, Warren J, Storer V. Catheter-related bloodstream infections caused by rapidly growing nontuberculous mycobacteria: a case series including care species. Diagn Microbiol Infect Dis 2008;61(2):187–91, doi:http://dx.doi.org/10.1016/j.diagmicrobio.2008.01.004.
[16] Paterson DL, Singh N, Gayowski T, Marino IR. Mycobacterium mucogenicum bacteraemia in a patient with cirrhosis. J Clin Gastroenterol 1998;27(4):346–7, doi:http://dx.doi.org/10.1097/00004836-199812000-00014.
[17] Han XY, De I, Jacobson KL. Rapidly growing mycobacteria: clinical and microbiologic studies of 115 cases. Am J Clin Pathol 2007;128(4):612–21, doi:http://dx.doi.org/10.1093/ACP/BCL009.
[18] Gaviria JM, Garcia PJ, Garrido SM, Corey I, Boeckh M. Nontuberculous mycobacterial infections in hematopoietic stem cell transplant recipients: characteristics of respiratory and catheter-related infections. Biol Blood Marrow Transplant 2000;6(4):361–9, doi:http://dx.doi.org/10.1016/S1083-8799(00)00212-7.
[19] Apisattikul N, Flynn PM, Hayden RT, Adderson EE. Infections caused by rapidly growing Mycobacteria spp in children and adolescents with cancer. J Pediatr Infect Dis Soc 2015;4(2):104–13, doi:http://dx.doi.org/10.1093/jpids/piu038.
[20] Redelman-Sidi G, Sepkowitz KA. Rapidly growing mycobacteria infection in patients with cancer. Clin Infect Dis 2010;51(4):422–34, doi:http://dx.doi.org/10.1086/655140.
[21] Reilly AF, McGowan KL. Atypical mycobacterial infections in children with cancer. Pediatr Blood Cancer 2004;43(6):698–702, doi:http://dx.doi.org/10.1002/pbc.20061.
[22] Fleming GA, Frangoul H, Dermosy TS, Halasa N. A cord blood transplant recipient with Mycobacterium mucogenicum central venous catheter infection after infusion of tap water. Pediatr Infect Dis J 2006;25(5):567–9, doi:http://dx.doi.org/10.1097/01.PID.0000219406.06431.67.
[23] Cooksey RC, Jhung MA, Yakrus MA, Butler WR, Adékambi T, Morlock GP, et al. Multiphasic approach reveals genetic diversity of environmental and patient isolates of Mycobacterium mucogenicum and Mycobacterium phocaicum associated with an outbreak of bacteraemias at a Texas hospital. Appl Environ Microbiol 2008;74(8):2480–7, doi:http://dx.doi.org/10.1128/AEM.02476-07.
[24] Marshall C, Samuel J, Galloway A, Pedder S. Mycobacterium mucogenicum from the Hickman line of an immunocompromised patient. J Clin Pathol 2007;61 (1):140–1, doi:http://dx.doi.org/10.1136/jcp.2007.049486.
[25] Al-Anzi KA, Al-Jasser AM, Al-Anzi WK. Infections caused by non-tuberculous mycobacteria in recipients of hematopoietic stem cell transplantation. Front Oncol 2014;4:311, doi:http://dx.doi.org/10.3389/fonc.2014.00311.